[A19-28] Galcanezumab (migraine) - Benefit assessment according to §35a Social Code Book V
Last updated 01.07.2019
Commission awarded on 29.03.2019 by the Federal Joint Committee (G-BA).
Head and nerves
Prophylaxis of migraine in adults who have at least 4 migraine days per month
Added benefit not proven for 2 of 3 research questions due to lack of study data. Adults with episodic or chronic migraine for whom otherwise best supportive care is the only option: indication of major added benefit.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A19-63||Galcanezumab (migraine) - Addendum to commission A19-28||Commission completed|
|G19-14||Galcanezumab (migraine) - Second Addendum to Commission A19-28||Commission completed|
Federal Joint Committee (G-BA)
2019-09-19 A G-BA decision was published.